ArticleDermatology practical & conceptual2025
Real-World Safety of Oral Isotretinoin in Patients During Sunny Months: Retrospective Cohort Study.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is a widespread clinical practice of avoiding oral isotretinoin administration during the sunny season due to its purported photosensitizing effect. However, this approach is not supported by solid evidence.
objectiveThe aim of this study was to assess the safety and effectiveness of administering oral isotretinoin at a reduced daily dosage during the sunny period in a real-world clinical setting.
methodsThis retrospective cohort study included all acne patients treated with oral isotretinoin at our Acne Clinic (January 2014 - December 2023) who had received the drug between June and September, when UV index exceeds a threshold of 6. Conventionally, oral isotretinoin daily dosage is reduced by approximately half during these four sunny months and then increased again. We compared the occurrence of side effects or treatment discontinuation between sunny and non-sunny periods. The therapeutic response was explored in relation to the daily dosage.
results359 patients (61.3% males, with a mean age of 19.0 years, standard deviation (SD) 6.7) were included. Adverse events were reported by 39.2% and 28.3% of patients during the non-sunny and sunny months, respectively. The incidence of treatment discontinuation was negligible. The reduction in acne severity was independent of the daily dosage of oral isotretinoin.
conclusionsThe study results support the lack of any necessity to suspend or refrain from administering oral isotretinoin during sunny seasons. The preventive reduction of its daily dosage during sunny periods does not negatively affect the drug's effectiveness. Oral isotretinoin can be taken, at a slightly reduced dosage, during sunny months.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.